Valneva SE (NASDAQ:VALN) is cutting its 2025 full-year sales and revenue guidance as a result of the US FDA’s August decision to revoke the marketing authorization for its chikungunya vaccine Ixchiq over safety concerns.
Product sales are now projected at €155M-€170M, down
